On April 21, the first batch of bivalent human papillomavirus vaccine (trade name: Xinkening , Cecolin) produced by Xiamen Wantai Canghai Biotechnology Co., Ltd. obtained the biological product batch issuance certificate from the State Food and Drug Administration. This means that the first domestic cervical cancer vaccine jointly developed by Xiamen University and Xiamen Wantai will be available soon. According to Zhang Xiang, deputy general manager of Xiamen Wantai, starting from May, most community hospitals in Hubei, Xinjiang, Jilin, Yunnan, Jiangsu, Shandong and other provinces and autonomous regions can make appointments for vaccination, and his company strives to cover the whole country by the end of the year.
The GSK approved by the National Food and Drug Administration and Merck’s HPV vaccine both require 3 doses, while the domestically produced Xinkening is suitable for women aged 9-45, covering a wider age range, with 2 doses for 9-14 years old, 15- 3 shots at the age of 45. In a community hospital in Putuo District, Shanghai, the price of the 9-valent HPV vaccine is about 1300 yuan per shot, the price of the quadrivalent HPV vaccine is about 800 yuan per shot, and the bivalent HPV vaccine is about 600 yuan per shot. The corresponding total vaccination costs are respectively Around 4000 yuan, 2400 yuan and 1800 yuan. The price of
Xinkening is 329 yuan per shot, which has a price advantage compared with imported HPV. The cost of two shots for 9-14 years old is 658 yuan, and the cost of three shots for 15-45 years old is 987 yuan. (Economic Observer Network, yx)
